Metabolic alterations in plasma from patients with familial and idiopathic Parkinson's disease.

Abstract

The research of new biomarkers for Parkinson's disease is essential for accurate and precocious diagnosis, as well as for the discovery of new potential disease mechanisms and drug targets. The main objective of this work was to identify metabolic changes that might serve as biomarkers for the diagnosis of this neurodegenerative disorder. For this, we profiled the plasma metabolome from mice with neurotoxin-induced Parkinson's disease as well as from patients with familial or sporadic Parkinson's disease. By using mass spectrometry technology, we analyzed the complete metabolome from healthy volunteers compared to patients with idiopathic or familial (carrying the G2019S or R1441G mutations in the LRRK2 gene) Parkinson's disease, as well as, from mice treated with 6-hydroxydopamine to induce Parkinson disease. Both human and murine Parkinson was accompanied by an increase in plasma levels of unconjugated bile acids (cholic acid, deoxycholic acid and lithocholic acid) and purine base intermediary metabolites, in particular hypoxanthine. The comprehensive metabolomic analysis of plasma from Parkinsonian patients underscores the importance of bile acids and purine metabolism in the pathophysiology of this disease. Therefore, plasma measurements of certain metabolites related to these pathways might contribute to the diagnosis of Parkinson's Disease.

• Authors: Sokhna M S Yakhine-Diop, José A Morales-García, Mireia Niso-Santano, Rosa A González-Polo, Elisabet Uribe-Carretero, Guadalupe Martinez-Chacon, Sylvere Durand, Maria Chiara Maiuri, Ana Aiastui, Miren Zulaica, Javier Ruíz-Martínez, Adolfo López de Munain, Jordi Pérez-Tur, Ana Pérez-Castillo, Guido Kroemer, José M Bravo-San Pedro, José M Fuentes
• Journal: Aging (Aging (Albany NY)) Vol. 12 Issue 17 Pg. 16690-16708 (Sep 09 2020) ISSN: 1945-4589 [Electronic] United States
• PMID: 32903216 (Publication Type: Journal Article)